The effects of L-alanine supplementation in late-onset glycogen storage disease type II

O. A.F. Bodamer, D. Halliday, J. V. Leonard

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Myopathy in glycogen storage disease type II (GSD-II) is slowly progressive. Five subjects with the late-onset form of GSD-II (age range, 15 to 47 years) and seven healthy control subjects (age range, 28 to 55 years) were studied. Following alanine supplementation, resting energy expenditure decreased in patients with GSD-II (p < 0.05) compared to values seen in control subjects. Leucine flux decreased (p < 0.004), as did leucine oxidation, to levels lower than those observed in control subjects (p < 0.001). L-Alanine reduces protein turnover and catabolism in GSD-II.

Original languageEnglish (US)
Pages (from-to)710-712
Number of pages3
JournalNeurology
Volume55
Issue number5
DOIs
StatePublished - 2000

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'The effects of L-alanine supplementation in late-onset glycogen storage disease type II'. Together they form a unique fingerprint.

  • Cite this